Skip to main content

View full-text article in PMC

. 2022 Oct 14;17(10):e0266617. doi: 10.1371/journal.pone.0266617

Table 4. Global Nephrocare group treatments.

	First visit	NRHP-UY assistance	p
RASB, n (%) (n = 11174)	6960 (62.3)	7906 (70.7)	0.000^a
Statins, n (%) (n = 11174)	4457 (39.9)	6431 (57.5)	0.000^a
Erythropoietin use, n (%) (n = 2825)^b	0	505 (17.9)	NC
Buffer agents, n (%) (n = 2556) ^b	0	663 (25.9)	NC
Influenza vaccine, n (%) (n = 5912)	881 (14.7)	3045 (51.5)	0.000^a
Pneumococcal vaccine, n (%) (n = 5912)	403 (6.8)	2204 (37.3)	0.000^a
Hepatitis B vaccine, n (%) (5912)	91 (1.5)	750 (12.7)	0.000^a

RASB = Renin-angiotensin system blockade, ^b in CKD IV-VND stages, n = number of patients with available paired-data in each variable.

^aMc Nemar’s paired samples test.